References
1. Zahid MF, Barraco D, Lasho TL, Finke C, Ketterling RP, Gangat N, et
al. Spectrum of autoimmune diseases and systemic inflammatory syndromes
in patients with chronic myelomonocytic leukemia. Leuk Lymphoma. 2017
Jun;58(6):1488–93.
2. Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK,
et al. A close association of autoimmune-mediated processes and
autoimmune disorders with chronic myelomonocytic leukemia: observation
from a single institution. Acta Haematol. 2015;133(2):249–56.
3. Grignano E, Mekinian A, Braun T, Liozon E, Hamidou M, Decaux O, et
al. Autoimmune and inflammatory diseases associated with chronic
myelomonocytic leukemia: A series of 26 cases and literature review.
Leuk Res. 2016 Aug;47:136–41.
4. Hadjadj J, Michel M, Chauveheid M-P, Godeau B, Papo T, Sacre K.
Immune thrombocytopenia in chronic myelomonocytic leukemia. Eur J
Haematol. 2014 Dec;93(6):521–6.
5. Wouters D, Zeerleder S. Complement inhibitors to treat IgM-mediated
autoimmune hemolysis. Haematologica. 2015 Nov;100(11):1388–95.
6. Fraison J-B, Mekinian A, Grignano E, Kahn J-E, Arlet J-B, Decaux O,
et al. Efficacy of Azacitidine in autoimmune and inflammatory disorders
associated with myelodysplastic syndromes and chronic myelomonocytic
leukemia. Leuk Res. 2016 Apr;43:13–7.
7. Scott LJ. Azacitidine: A Review in Myelodysplastic Syndromes and
Acute Myeloid Leukaemia. Drugs. 2016 May;76(8):889–900.
8. Röth A, Bommer M, Hüttmann A, Herich-Terhürne D, Kuklik N, Rekowski
J, et al. Eculizumab in cold agglutinin disease (DECADE): an open-label,
prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018
09;2(19):2543–9.
9. Ma K, Caplan S. Refractory IgG Warm Autoimmune Hemolytic Anemia
Treated with Eculizumab: A Novel Application of Anticomplement Therapy.
Case Rep Hematol. 2016;2016:9181698.
10. Meulenbroek EM, de Haas M, Brouwer C, Folman C, Zeerleder SS,
Wouters D. Complement deposition in autoimmune hemolytic anemia is a
footprint for difficult-to-detect IgM autoantibodies. Haematologica.
2015 Nov;100(11):1407–14.
11. Benamu E, Montoya JG. Infections associated with the use of
eculizumab: recommendations for prevention and prophylaxis. Curr Opin
Infect Dis. 2016;29(4):319–29.
12. Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet
A-S, et al. Efficacy and safety of rituximab in auto-immune hemolytic
anemia: A meta-analysis of 21 studies. Autoimmun Rev. 2015
Apr;14(4):304–13.
13. Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S,
et al. Long-term follow-up analysis after rituximab salvage therapy in
adult patients with immune thrombocytopenia. Am J Hematol. 2012
Sep;87(9):886–9.